Research Network for Metals in Medicine

 

 

Associate Professor Michael Boyer

MBBS, PhD, FRACP

Position: Head Medical Oncology, Sydney Cancer Centre
Senior Staff Specialist, Royal Prince Alfred Hospital
Clinical Associate Professor, University of Sydney

Affiliation: Sydney Cancer Centre

Postal Address:
Sydney Cancer Centre
Level 6, Gloucester House
Royal Prince Alfred Hospital
Missenden Road
Camperdown NSW 2050
AUSTRALIA

Phone: +61 (2) 9515 6018
Fax: +61 (2) 9515 7404
Email: Michael.Boyer@cs.nsw.gov.au
Webpage: http://www.sydneycancer.com.au/about/bios.html#boyer

Research Profile

Michael Boyer is an academic oncologist with over ten years experience in the management of cancer patients and in cancer clinical trials. His research over the past few years has focused on clinical trials of new anti-cancer agents and cancer imaging. These studies include a large randomised trial of PET scanning, as well as several clinical trials which have been established and then co-ordinated on a nationwide basis by Dr Boyer. Over the past 5 years he has been the principal investigator on 10 clinical trials. In addition, he has collaborated with Martin Tattersall and Phyllis Butow on several projects relating to doctor-patient communication in the cancer consultation. He has been an investigator in several of these studies, and a participant in others. His research has been published predominantly in major cancer journals. The current application extends his collaboration with the other principal investigators, and builds on his experience in communication research.

Selected Publications

  1. von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P, et al. Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non-small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group. J Clin Oncol, 2000; 18: 1351-1359.
  2. Rischin D, Boyer M, Smith J, et al. A phase I trial of docetaxel and gemcitabine in patients with advanced cancer. Ann Oncol, 2000; 11: 421-426.
  3. Rischin D, Smith J, Millward M, Lewis C, Boyer M, Richardson G, Toner G, Gurney H, McKendrick J. A phase II trial of paclitaxel and epirubicin in advanced breast cancer. Br J Cancer, 2000; 83: 438 - 442.
  4. Rivory LP, Slaviero K, Seale JP, Hoskins JM, Boyer M, Beale PJ, Millward MJ, Bishop JF, Clarke SJ. Optimising the erythromycin breath test for use in cancer patients. Clinical Cancer Research, 2000; 6: 3480 - 3485.
  5. Boyer MJ, Mitchell P, Goldstein D, Millward MJ, Olver IN, Clarke SJ, Richardson G, Davis I. Phase II study of paclitaxel and oral etoposide in patients with locally advanced or metastatic non-small cell lung cancer. Lung Cancer, 2001; 32: 89 - 94.
  6. Toner G, Stockler MR, Boyer MJ, Jones M, Thompson DB, Harvey VJ, et al Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumours: a randomised trial. Lancet, 2001; 357: 739 - 745.
  7. Horvath LG, Boyer MJ, Clarke SJ, Beale P, Beith J, Underhill C, Stockler M, Bishop J. Carboplatin and Vinorelbine in untreated locally advanced and metastatic non-small cell lung cancer. Lung Cancer, 2001; 32: 173 - 178.
  8. Twelves C, Boyer M, Findlay M, Cassidy J, Weitzel C, Barker C, et al. Capecitabine improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer, 2001; 37: 597 - 604.
  9. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol, 2001; 19: 4097 - 4106.
  10. Rivory LP, Clarke SJ, Boyer M, Bishop JF. Highly sensitive analysis of the antifolate pemetrexed sodium, a new cancer agent, in human plasma and urine by high-prtformance liquid chromatography. Journal of Chromatography B, 2001; 765: 135 - 140.
  11. Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Millward MJ, Ackland SP. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapay mnaive patients with advanced non-small-cell lung cancer (NSCLC). Ann Onc, 2002; 13: 737 - 741.
  12. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favourable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol, 2002; 13: 566 - 575.
  13. Boyer MJ, Rosenthal MA, Eisinger D, Goad J, Webb D, Stockler MR. Adjuvant mitoxantrone chemotherapy for men at high risk of relapse following radical prostatectomy: a pilot study. UroOncology, 2002; 2: 15 - 17.
  14. Boyer MJ, Rivory LP, Clarke SJ. Pemetrexed: single agent and combination phase I study overview. Semin Oncol, 2002; 29, Suppl 18: 18 - 23.
  15. Millward MJ, Boyer MJ, Lehnert M, et al. Docetaxel and carboplatin is an active regimen in advanced non-small cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol, 2003; 14: 449 - 454.
  16. Boyer M, Byrne M, Clarke S. Alimta: a new treatment option for malignant mesothelioma. Reviews in Clinical Oncology, 2003; 1: 4 - 8.
  17. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol, 2003; 21: 2636 - 2644.
  18. Zhang M, Boyer M, Rivory L, et al. Radiosensitization of vinorelbine and gemcitabine in NCI-H460 non-small cell lung cancer cells. Int J Radiation Oncology Biol Phys, 2004; 58: 353 - 360.


Facilities

Dr Boyer Provides the Network with expertise in conducting clinical trials of new agents for the treatment and imaging of cancer. He has particular interests in genitourinary cancer and lung cancer.